PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20237821-7 2010 Following treatment with TNF-alpha or PMA, ANXA4 also suppressed NF-kappaB transcriptional activity, which was upregulated significantly early after etoposide treatment. Etoposide 149-158 tumor necrosis factor Homo sapiens 25-34 25890358-12 2015 Moreover, TNFalpha sensitized NBL cells to DNA-damaging agents (i.e. cisplatin and etoposide) that induce the expression of FasL. Etoposide 83-92 tumor necrosis factor Homo sapiens 10-18 25890358-13 2015 Priming to FasL-, cisplatin-, and etoposide-induced cell death could only be achieved in NBLs that display TNFalpha-induced upregulation of Fas. Etoposide 34-43 tumor necrosis factor Homo sapiens 107-115 25890358-15 2015 CONCLUSIONS: In summary, our findings reveal that TNFalpha sensitizes NBL cells to FasL-induced cell death by NF-kappaB-mediated upregulation of Fas and unveil a new mechanism through which TNFalpha enhances the efficacy of currently used NBL treatments, cisplatin and etoposide. Etoposide 269-278 tumor necrosis factor Homo sapiens 50-58 25890358-15 2015 CONCLUSIONS: In summary, our findings reveal that TNFalpha sensitizes NBL cells to FasL-induced cell death by NF-kappaB-mediated upregulation of Fas and unveil a new mechanism through which TNFalpha enhances the efficacy of currently used NBL treatments, cisplatin and etoposide. Etoposide 269-278 tumor necrosis factor Homo sapiens 190-198 21555371-3 2011 We show here that exposure of tumor cells to TGFbeta and TNFalpha induces EMT and, more importantly, generates cells with a stable BCSC phenotype which is shown by increased self-renewing capacity, greatly increased tumorigenicity, and increased resistance to oxaliplatin, etoposide, and paclitaxel. Etoposide 273-282 tumor necrosis factor Homo sapiens 57-65 25890358-0 2015 TNFalpha sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-kappaB-mediated expression of Fas. Etoposide 65-74 tumor necrosis factor Homo sapiens 0-8 22027829-5 2011 We show that HSS-7 associates with topoisomerase IIalpha (Top2) in vivo and that induction of endogenous TNF mRNA expression is suppressed by etoposide, a Top2 inhibitor. Etoposide 142-151 tumor necrosis factor Homo sapiens 105-108 15273737-3 2004 TNFalpha pretreatment resulted in enhanced cleavage and activity of caspase-3 upon addition of etoposide, epirubicin or ceramide. Etoposide 95-104 tumor necrosis factor Homo sapiens 0-8 15507659-4 2004 Treatment with tumor necrosis factor alpha did not induce apoptosis of EBNA2- or EBNA2DeltaCR4-expressing cells, but EBNA2DeltaCR4 cells were susceptible to etoposide and 5-fluorouracil, Nur77-mediated inducers of apoptosis. Etoposide 157-166 tumor necrosis factor Homo sapiens 15-42 12815281-8 2003 Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10. Etoposide 78-87 tumor necrosis factor Homo sapiens 173-181 12207175-2 2002 Here we report that overexpression of Je2 in CEM-C7 T-cell line is able to suppress CD95-mediated apoptosis, and apoptosis induced by TNFalpha and the glucocorticoid analogue dexamethasone, but was not able to suppress death induced by the topoisomerase II inhibitor etoposide. Etoposide 267-276 tumor necrosis factor Homo sapiens 134-142 11244505-3 2001 Blockade of NF-kappaB activation by various NF-kappaB inhibitors abolished TNFalpha-induced p22PRG1/IEX-1 expression and increased the sensitivity to apoptosis induced by TNFalpha, an activating Fas-antibody or the anti-cancer drug etoposide. Etoposide 232-241 tumor necrosis factor Homo sapiens 75-83 11244505-3 2001 Blockade of NF-kappaB activation by various NF-kappaB inhibitors abolished TNFalpha-induced p22PRG1/IEX-1 expression and increased the sensitivity to apoptosis induced by TNFalpha, an activating Fas-antibody or the anti-cancer drug etoposide. Etoposide 232-241 tumor necrosis factor Homo sapiens 171-179 8858979-4 1996 TNF endogenously secreted by human ovarian cancer cell lines is very efficient in potentiating the activity of DNA topoisomerase II inhibitors (doxorubicin, mitoxantrone, VP16). Etoposide 171-175 tumor necrosis factor Homo sapiens 0-3 10440872-12 1999 In contrast, CDDP, VP-16, and the protein synthesis inhibitors, Act-D and CHX sensitized DU145 cells to TNF-alpha killing. Etoposide 19-24 tumor necrosis factor Homo sapiens 104-113 10092213-6 1998 On the other hand, whereas the transfection of the hsp27 gene increased the cell resistance to heat in both cell lines, only in SaOS-2 cells was this associated with protection to the cytotoxic action of tumor necrosis factor-alpha (TNF-alpha) and etoposide. Etoposide 248-257 tumor necrosis factor Homo sapiens 233-242 2171561-7 1990 Tumor necrosis factor alone inhibited the growth and cloning of the NSCLC line H125 but exerted a marked protective effect against higher concentrations of etoposide. Etoposide 156-165 tumor necrosis factor Homo sapiens 0-21 7654031-5 1995 This effect was due to an increase in the VP 16-induced cleavable-complexes by TNF. Etoposide 42-47 tumor necrosis factor Homo sapiens 79-82 7654031-6 1995 These findings suggest that TNF specifically sensitizes human glioma T98G cells to the effects of VP 16 of VM26. Etoposide 98-103 tumor necrosis factor Homo sapiens 28-31 7597304-10 1995 There is convincing evidence that the synergy between tumor necrosis factor (TNF) and topoisomerase-targeted intercalative (Adriamycin, doxorubicin hydrochloride; m-AMSA, amsacrine; mitoxantrone) and nonintercalative (VM-16, etoposide; VM-26, teniposide) drugs is related to a rapid increase in specific activity of topoisomerase I and II, resulting in enhanced DNA strand breaks and cleavage complex. Etoposide 225-234 tumor necrosis factor Homo sapiens 54-75 1336489-1 1992 Recombinant human tumor necrosis factor (rHuTNF) synergistically potentiates the cytotoxicity of the topoisomerase I inhibitor camptothecin, and the topoisomerase II inhibitors epidoxorubicin, etoposide, mitoxantrone, ellipticine, actinomycin D and 4"-(9-acridinylamino)methanesulfon-m-anisidide on A2780 human ovarian cancer cell line. Etoposide 193-202 tumor necrosis factor Homo sapiens 18-39 1779333-2 1991 Recombinant human tumor necrosis factor (rhTNF) has been shown to enhance the antitumor efficacy of etoposide (VP-16) in the treatment of C1300 murine neuroblastoma. Etoposide 100-109 tumor necrosis factor Homo sapiens 18-39 1779333-2 1991 Recombinant human tumor necrosis factor (rhTNF) has been shown to enhance the antitumor efficacy of etoposide (VP-16) in the treatment of C1300 murine neuroblastoma. Etoposide 111-116 tumor necrosis factor Homo sapiens 18-39 2171561-4 1990 The effects of etoposide on the classic SCLC line H209 were potentiated by TNF with a decrease in the IC50 from 3.3 microM to 1.0 microM as determined by FDA/PI. Etoposide 15-24 tumor necrosis factor Homo sapiens 75-78 2166714-6 1990 With 5 cell lines we also tested whether TNF affected the cytotoxicity of doxorubicin and etoposide, 2 topoisomerase II-targeted drugs which are widely used in the therapy of lung cancer. Etoposide 90-99 tumor necrosis factor Homo sapiens 41-44 2171561-8 1990 It appears that the interaction of TNF with etoposide varies between cell lines and between subclasses of human lung cancer. Etoposide 44-53 tumor necrosis factor Homo sapiens 35-38 32238729-4 2020 Administration of steroid and high-dose intravenous immunoglobulin (1 g/kg) did not alleviate fever or reduce cytokine production; however, after administration of etoposide (an antineoplastic agent), fever decreased immediately, the patient"s general condition improved, and levels of IL-6, IL-10, IL-8, MCP-1, IFN-gamma, and TNF-alpha declined after etoposide administration. Etoposide 164-173 tumor necrosis factor Homo sapiens 327-336 2219586-0 1990 Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Etoposide 78-87 tumor necrosis factor Homo sapiens 51-72 31411059-12 2019 mRNA expression of proinflammatory and profibrotic factors (TNF-alpha, IL-1, IL-8, MMP3) was elevated by hyperoxia or etoposide. Etoposide 118-127 tumor necrosis factor Homo sapiens 60-69